Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

REVIEW

[Clinical significance of and treatment options for increased lipoprotein(a)]

Noémi Zsíros, György Paragh, Mariann Harangi

Orvosi Hetilap 2014 April 20, 155 (16): 607-14

Lipoprotein(a) has been shown to be associated with an increased incidence of cardiovascular diseases for decades. However, only recent research revealed more about its physiological function and its role in the development of cardiovascular diseases. The authors summarize the physiological role of lipoprotein(a), causes and treatment of elevated lipoprotein(a) level, and the association between lipoprotein(a) and cardiovascular diseases.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Latest developments in the treatment of lipoprotein (a). Sven Bos, Reyhana Yayha, Jeanine E Roeters van Lennep Current Opinion in Lipidology 2014, 25 (6): 452-60

Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Josef Leebmann, Eberhard Roeseler, Ulrich Julius, Franz Heigl, Ralf Spitthoever, Dennis Heutling, Paul Breitenberger, Winfried Maerz, Walter Lehmacher, Andreas Heibges, Reinhard Klingel Circulation 2013 December 17, 128 (24): 2567-76

Hyperlipoproteinemia(a): clinical significance and treatment options. Heiner K Berthold, Ioanna Gouni-Berthold Atherosclerosis. Supplements 2013, 14 (1): 1-5

Ongoing challenges for pharmacotherapy for dyslipidemia. Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka, Stephen J Nicholls Expert Opinion on Pharmacotherapy 2015, 16 (3): 347-56

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Z Reiner Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 2013, 23 (9): 799-807

Lipoprotein(a): medical treatment options for an elusive molecule. Klaus G Parhofer Current Pharmaceutical Design 2011, 17 (9): 871-6

[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. László Bajnok Orvosi Hetilap 2014 January 12, 155 (2): 62-8

What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? Mohamed H Ahmed Journal of Cardiovascular Medicine 2010, 11 (11): 858-60

Novel strategies for managing dyslipidemia: treatment beyond statins. Hua Ling, Tammy L Burns, Daniel E Hilleman Postgraduate Medicine 2012, 124 (6): 43-54

The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future. R Hajhosseiny, I Sabir, K Khavandi, A S Wierzbicki Clinical Pharmacology and Therapeutics 2014, 96 (1): 64-73

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

[Clinical significance of and treatment options for increased lipoprotein(a)]

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips